Market Overview

LabCorp Clinical Trials Enters 5-Year Agreement with Bristol-Myers Squibb

Related LH
The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum
10 Biggest Price Target Changes For Thursday
Goldman bullish on Insmed in premarket analyst action (Seeking Alpha)

Laboratory Corporation of America Holdings
(NYSE: LH) today announced that LabCorp Clinical Trials has been selected
as a preferred provider for full-service global central laboratory
services and biomarker testing by Bristol-Myers Squibb Company (NYSE: BMY).

The five-year agreement builds on a long-standing partnership between
the two companies during which LabCorp's global central lab, biomarker
and specialty testing capabilities have supported various Bristol-Myers
Squibb early and late-stage clinical development programs.

“We are excited to expand our relationship with Bristol-Myers Squibb to
provide a more flexible and integrated approach to laboratory testing
services in support of their innovative clinical development pipeline,”
said Dr. Mark Brecher, LabCorp's Chief Medical Officer.

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (BMY + LH)

View Comments and Join the Discussion!

Benzinga Market Primer: Monday, April 1

Acacia Subsidiary Enters into License Agreement with Ventyx USA